P

Philips

Makes medical devices and personal health products

Clinical Strategy Specialist - Ambulatory Monitoring & Diagnostics

Full-Time
$134k - $148k/yr
Mid
Bachelor of Science (BS)
Dallas, TX, USA+2 moreMore locations: Denver, CO, USA | San Diego, CA, USA
In PersonField role; must reside in or near the region and close to a metropolitan airport. Travel up to 75% may be required.
Solution Engineering
No H1B Sponsorship

About the job

Requirements
  • A Bachelor of Science in Nursing (BSN) or equivalent experience and a current, unrestricted Registered Nurse (RN) license.
  • A minimum of three years of progressive clinical experience in cardiovascular care, electrophysiology, emergency medicine, critical care, neurology, ambulatory care, or related specialties.
  • Demonstrated success developing and implementing clinical care pathways, workflow optimization initiatives, or quality improvement programs.
  • Strong knowledge of ambulatory cardiac monitoring, cardiac rhythm interpretation, arrhythmia management, and evidence-based clinical practice.
  • Experience leading multidisciplinary initiatives and collaborating with physicians, nursing, operations, information technology, and executive leadership.
  • Communication, presentation, facilitation, and relationship-building skills, with the ability to influence without direct authority, translate clinical expertise into measurable business value, and manage multiple strategic customer initiatives.
  • Proficiency with electronic medical records, Microsoft Office applications, and business analytics tools.
  • Willingness to travel up to 75% or as required.
  • Ability to successfully perform the minimum physical, cognitive, and environmental requirements for the sales position.
  • US work authorization is required, and candidates requiring sponsorship for a work-authorized visa now or in the future will not be considered.
  • Residence in or within the region and near a metropolitan airport.
Responsibilities
  • Shape clinical strategy for key customer partnerships by aligning ambulatory monitoring programs with customer goals, growth opportunities, and measurable value.
  • Partner with Account Executives and customer leaders to uncover clinical needs, strengthen relationships, and support long-term retention and expansion.
  • Assess customer clinical programs and create practical roadmaps that advance monitoring maturity across service lines, workflows, and enterprise initiatives.
  • Design and implement evidence-based care pathways, standardized protocols, and optimized workflows that improve patient selection, utilization, outcomes, and operational efficiency.
  • Serve as a clinical subject matter expert, educate healthcare professionals, and guide multidisciplinary teams through sustainable change.
  • Build relationships with physician champions, nursing leadership, operational teams, quality organizations, and executive sponsors to accelerate adoption and program success.
  • Define success measures, monitor clinical and operational performance, and lead business reviews highlighting outcomes, customer impact, and opportunities for continued improvement.
  • Translate clinical results into operational, financial, and strategic value stories that position Philips as a trusted partner in improving care.

About the company

Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.

Company Size

10,001+

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Get referred to Philips

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
  • Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
  • Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.

What critics are saying

  • US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
  • Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
  • Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.

What makes Philips unique

  • MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
  • Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
  • The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.